^
Association details:
| Biomarker: | KRAS G12D + DNMT3A C559fsX |
|---|---|
| Cancer: | Sarcoma |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + daunorubicin (Topoisomerase II inhibitor, DNA intercalator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case report: Rare myeloid sarcoma development following renal transplantation with KRAS and DNMT3A gene mutations
Published date:
08/31/2021
Excerpt:
NGS examinations...showed mutations of KRAS (NM_004985:exon2:c.G35A:p.G12Drs121913529), DNMT3A (NM_022552:exon15:c.1675delT:p.C559fs)...The patient underwent systemic chemotherapy in our hospital in October 2019, and received DA regimen chemotherapy (daunorubicin 100 mg on days 1-3 and cytarabine 170 mg on days 1-7). The patient responded well to the treatment, and the size of the mass in the transplanted kidney decreased and the level of sCr decreased to 192 mmol/L.
DOI:
10.1186/s13000-021-01141-z
